Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23885771 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL29183209 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL21748791 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL3116551 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL3124376 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL28502789 | 0.98 | GNAI3 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL28502790 | 0.98 | GNAI3 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL22496874 | 0.84 | LMNA (0.37) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL2377686 | 0.84 | EPHX2 (0.37) | ALDH1A1NPC1CHRNA7 | |
| SCHEMBL16169058 | 0.84 | EPHX2 (0.37) | ALDH1A1NPC1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174664-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2024-05-30 | — | — | US | disclosed |
| US-20240150340-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| WO-2024077216-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| US-11851426-B2 | Bicyclic amines as CDK2 inhibitors | INCYTE CORPORATION (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230257394-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-17 | — | — | US | disclosed |
| WO-2023150612-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230024173-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-01-26 | — | — | US | disclosed |
| WO-2021072232-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20210107901-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
| US-20210047294-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-02-18 | — | — | US | disclosed |
| US-20210017156-A1 | PYRAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-01-21 | — | — | US | disclosed |
| US-20200347067-A1 | TRICYCLIC AMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2020-11-05 | — | — | US | disclosed |
| WO-2020223469-A1 | N-(1-(METHYLSULFONYL)PIPERIDIN-4-YL)-4,5-DI HYDRO-1H-IMIDAZO[4,5-H]QUINAZOLIN-8-AMINE DERIVATIVES AND RELATED COMPOUNDS AS CYCLIN-DEPENDENT KINASE 2 (CDK2) INHIBITORS FOR TREATING CANCER | INCYTE CORPORATION (US) | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017156-A1 | PYRAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK2AP2, CDK4 | ALDH1A1 3715/4885ACHE 4492/4885NPC1 3538/4885 |
| US-20210047294-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | ALDH1A1 3723/4885ACHE 4631/4885NPC1 3231/4885 |
| US-20240150340-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | ALDH1A1 2921/4885ACHE 3685/4885NPC1 3950/4885 |
| US-20230024173-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | ALDH1A1 3723/4885ACHE 4631/4885NPC1 3231/4885 |
| US-11851426-B2 | Bicyclic amines as CDK2 inhibitors | CDK2, CDK1, CCNI | ALDH1A1 2576/4885ACHE 2870/4885NPC1 3516/4885 |
| US-20230257394-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | ALDH1A1 2921/4885ACHE 3685/4885NPC1 3950/4885 |
| US-20240174664-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CDK2, CDK1, CCNI | ALDH1A1 2576/4885ACHE 2870/4885NPC1 3516/4885 |
| US-20200347067-A1 | TRICYCLIC AMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK1, CCNI | ALDH1A1 4033/4885ACHE 2734/4885NPC1 3606/4885 |
| US-20210107901-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CDK2, CDK1, CCNI | ALDH1A1 2576/4885ACHE 2870/4885NPC1 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.